Mais conteúdo relacionado Semelhante a Antibiotic Discovery Webinar – Getting Through the Discovery Wall (20) Antibiotic Discovery Webinar – Getting Through the Discovery Wall1. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
“Antibiotic Discovery –
Getting Through the Discovery Wall”
Town Hall Webinar
September 20, 2017
2. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Today’s Guest
Moderator
Antibiotic Discovery – Getting Through the Discovery Wall
Joseph Thomas
Associate, The Pew Charitable
Trusts -
Antibiotic Resistance Project
Today’s Panelists
Lynn Silver
Silver Consulting
Providing expert services in
antibacterial drug discovery
and preclinical development.
Johannes Zuegg
Program Coordinator
Logistics & Chemoinformatics at
CO-ADD
3. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Adapted from Lynn L. Silver, “Challenges of Antibacterial Discovery,” Clinical Microbiology Reviews 24, no. 1. (2011): 71-109.
Adapted from Lynn L. Silver, “Challenges of Antibacterial Discovery,” Clinical Microbiology
Reviews 24, no. 1. (2011): 71-109
Antibiotic Discovery – Getting Through the Discovery Wall
4. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
5. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
6. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
7. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
8. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
9. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
190, 052
compounds
screened
CO-ADD has screened >twice the
number of any other screening
program so far disclosed.
McGilvray A. (2016) Nat 533, S65-7
HIT RATES [MIC ≤ 16 µg/mL]
No Cytotox
0.25% for G+ve
0.07% for G-ve
0.48% for fungi
Antibiotic Discovery – Getting Through the Discovery Wall
10. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
11. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
12. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
GN Barriers (simplistic view)
OM
CM
periplasm
LPS &O-Ag
OM excludes hydrophobic and hydrophilic compounds.
Penetration of hydrophilic compounds through OM is via porins
But hydrophilic and highly charged molecules entering the periplasm
penetrate the CM slowly or not at all
unless actively transported [or via PMF]
Molecules that do enter can be effluxed
What molecules can accumulate in the GN cytoplasm?
13. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
Antibiotic Discovery – Getting Through the Discovery Wall
14. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
15. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery WallAntibiotic Discovery – Getting Through the Discovery Wall
16. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Collaborating Scientists!
Antibiotic Discovery – Getting Through the Discovery Wall
17. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Where we need funding
NIH, ENABLE CARB-X
Sources: Michael J. Fox Foundation for Parkinson’s Research; FasterCures
Antibiotic Discovery – Getting Through the Discovery Wall
19. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Binning cytoplasmic drugs
-14
-12
-10
-8
-6
-4
-2
0
2
4
6
8
0 200 400 600 800 1000 1200 1400
GN diffusion
GN transported
Aminoglycosides (SPU)
GP only diffusion
Triclosan
cLogD7.4
MW
20. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
21. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
22. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
23. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
24. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
25. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Aims from the Pew Roadmap
• A better understanding of how to overcome the cellular defenses
of drug-resistant Gram-negative bacteria, which cause some of the
most difficult-to-treat infections.
• Generation of new chemical matter designed for antibiotic
discovery.
• Tools and methodologies to evaluate promising alternatives to
traditional antibiotic use.
26. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
Questions?
27. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Today’s Guest
Moderator
CONTACT US Antibiotic Discovery – Getting Through the Discovery Wall
Joseph Thomas
Associate, The Pew Charitable
Trusts -
Antibiotic Resistance Project
Contact:
jthomas@pewtrusts.org
Today’s Panelists
Lynn Silver
Silver Consulting
Providing expert services in
antibacterial drug discovery
and preclinical development.
Contact:
silverly@comcast.net
Johannes Zuegg
Program Coordinator
Logistics & Chemoinformatics at
CO-ADD
Contact:
j.zuegg@imb.uq.edu.au
28. Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Antibiotic Discovery – Getting Through the Discovery Wall
THANK YOU
For further contact with CDD:
info@collaborativedrug.com